Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Additional Information (Details)

v3.22.0.1
Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
segment
item
shares
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Summary Of Significant Accounting Policies [Line Items]      
Number of operating segment | segment 1    
Number of financial instruments with off-balance sheet risk | item 0    
Depreciation $ 2,758 $ 2,774 $ 2,521
Impairment losses 0 0 0
Revenue $ 23,488 $ 15,093 $ 1,982
Warrant issued to purchase common stock | shares 2,117,094 2,117,094 2,118,094
Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted | shares 62,534,978 46,051,617 40,222,182
ASU 2019-12      
Summary Of Significant Accounting Policies [Line Items]      
Change in accounting principle, accounting standards update, adopted true    
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2021    
Change in accounting principle, accounting standards update, immaterial effect true    
Private Placement      
Summary Of Significant Accounting Policies [Line Items]      
Warrant issued to purchase common stock | shares 2,828,125 2,828,125  
Pre-Funded Warrant | Private Placement      
Summary Of Significant Accounting Policies [Line Items]      
Warrant issued to purchase common stock | shares 1,000,000 1,000,000  
Performance-based stock options | Executive Officers      
Summary Of Significant Accounting Policies [Line Items]      
Compensation expense recognized period 6 years    
Global Blood Therapeutics      
Summary Of Significant Accounting Policies [Line Items]      
Revenue $ 19,400 $ 11,700  
Incyte      
Summary Of Significant Accounting Policies [Line Items]      
Revenue 4,100 $ 3,400 $ 2,000
Construction in progress      
Summary Of Significant Accounting Policies [Line Items]      
Depreciation $ 0